Abbott Laboratories

Report azionario NYSE:ABT

Capitalizzazione di mercato: US$197.5b

Abbott Laboratories Performance degli utili passati

Criteri Il passato verificati 2/6

Abbott Laboratories ha registrato una crescita degli utili a un tasso medio annuo di 7.3%, mentre il settore Medical Equipment ha registrato utili in crescita a un tasso medio annuo di 14.8%. I ricavi sono stati in crescita a un tasso medio annuo di 0.7%. Il ritorno sul capitale proprio di Abbott Laboratories è 10.5% e ha margini netti di 11.6%.

Informazioni chiave

7.34%

Tasso di crescita degli utili

7.78%

Tasso di crescita dell'EPS

Medical Equipment Crescita del settore8.90%
Tasso di crescita dei ricavi0.73%
Rendimento del capitale proprio10.48%
Margine netto11.59%
Ultimo aggiornamento sugli utili30 Jun 2026

Aggiornamenti sulle prestazioni recenti

Recent updates

Seeking Alpha • Aug 19

Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-Term

Summary Abbott Laboratories remains a buy, with accelerating earnings growth, margin expansion, and robust segment performance following Q2’s double beat and guidance raise. ABT’s Exact Sciences acquisition strengthens its long-term growth runway, supporting a raised EPS outlook and 10.4% CAGR over the next six years. Despite recent price appreciation, ABT trades below its 5-year forward P/E average, offering a 2.5% yield and a potential 37% upside to a $151 price target. Risks include Nutrition segment volatility, regulatory scrutiny on the pipeline, and international exposure, but ABT’s A credit rating and Dividend King status support a premium valuation. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 23

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Drive Future Repricing

Abbott Laboratories' fair value estimate has moved from $116.54 to $119.13. This reflects analysts' higher price targets in the $112 to $121 range after Q2 results that were viewed as better than expected and supported by updated models and confidence in longer term growth drivers.
Articolo di analisi • Jun 21

Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings

Dividend affirmation and earnings catalyst put Abbott Laboratories stock in focus Recent commentary on Abbott Laboratories (ABT) has centered on upcoming earnings and Citi highlighting the value of its diversified healthcare businesses, setting the stage for closer attention to the stock. The reaffirmed quarterly dividend and the approaching July 16 earnings report give investors timely reference points as they weigh Abbott Laboratories stock, its current business mix, and expectations around...
Aggiornamento narrativa • Jun 16

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower from about $117.29 to $116.54, reflecting a series of reduced Street price targets that cite utilization and inflation headwinds, while still applying a modestly lower discount rate and a slightly softer future P/E assumption. Analyst Commentary Recent Street research on Abbott Laboratories points to a more cautious tone, with many price targets cut and utilization and inflation flagged as key issues.
Aggiornamento narrativa • Jun 02

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower to about $117.29 from $118.64. This reflects a series of reduced price targets and more cautious outlooks on growth and valuation across recent research updates.
Aggiornamento narrativa • May 12

ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.
Aggiornamento narrativa • Apr 23

ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.
Aggiornamento narrativa • Apr 09

ABT: AF Portfolio And Dividend Track Record Will Support Future Upside

Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.
Aggiornamento narrativa • Mar 26

ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside

Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.
Aggiornamento narrativa • Mar 11

ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside

Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.
Aggiornamento narrativa • Feb 24

ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside

Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.
Aggiornamento narrativa • Feb 10

ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside

Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.
Aggiornamento narrativa • Jan 26

ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential

Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.
Aggiornamento narrativa • Jan 11

ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside

Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.
Articolo di analisi • Jan 03

Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
Aggiornamento narrativa • Dec 27

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns

Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.
Aggiornamento narrativa • Dec 12

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside

Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.
Aggiornamento narrativa • Nov 28

ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside

Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.
Aggiornamento narrativa • Nov 14

ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains

Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.
Articolo di analisi • Nov 05

Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem

Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Aggiornamento narrativa • Oct 31

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.
Aggiornamento narrativa • Oct 16

Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds

Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.
Articolo di analisi • Sep 15

There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings

With a price-to-earnings (or "P/E") ratio of 16.7x Abbott Laboratories ( NYSE:ABT ) may be sending bullish signals at...

Ripartizione dei ricavi e delle spese

Come Abbott Laboratories guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NYSE:ABT Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
30 Jun 2646,5855,40113,2183,107
31 Mar 2645,1346,25212,2972,940
31 Dec 2544,3286,50011,6302,889
30 Sep 2543,84313,97511,4872,935
30 Jun 2543,10913,97711,3442,882
31 Mar 2542,34413,50011,1962,855
31 Dec 2441,95013,40011,1092,823
30 Sep 2441,2175,76110,9212,673
30 Jun 2440,7255,54610,7622,632
31 Mar 2440,3265,60810,5702,649
31 Dec 2340,1095,70010,3852,619
30 Sep 2339,9595,14210,5832,619
30 Jun 2340,2265,14010,6112,729
31 Mar 2341,5055,78510,6572,698
31 Dec 2243,6536,90510,7032,741
30 Sep 2245,0307,85710,9012,921
30 Jun 2245,5488,52010,9712,811
31 Mar 2244,5147,69510,9782,781
31 Dec 2143,0757,04211,0062,738
30 Sep 2142,3087,20810,5932,623
30 Jun 2140,2336,34310,2442,531
31 Mar 2137,3385,6939,8072,441
31 Dec 2034,6084,4499,5912,420
30 Sep 2032,2213,3469,4052,289
30 Jun 2031,4443,0739,4402,305
31 Mar 2032,0953,5399,5972,318
31 Dec 1931,9043,6669,5402,440
30 Sep 1931,3553,2729,4522,395
30 Jun 1930,9352,8679,4032,373
31 Mar 1930,7232,5829,4482,371
31 Dec 1830,5782,3199,5682,298
30 Sep 1830,4028029,4822,280
30 Jun 1829,5758129,1412,274
31 Mar 1828,4453658,8682,219
31 Dec 1727,3903448,8042,183
30 Sep 1725,1341,9718,1751,979
30 Jun 1723,6071,0557,8081,763
31 Mar 1722,3031,3847,3951,575
31 Dec 1620,8531,0566,5581,442
30 Sep 1620,7089896,6201,353
30 Jun 1620,5561,9396,6581,379
31 Mar 1620,3932,1246,6481,392
31 Dec 1520,4052,5866,7421,371
30 Sep 1520,5732,5236,5931,338

Guadagni di qualità: ABT ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di ABT (11.6%) sono inferiori rispetto allo scorso anno (32.4%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di ABT sono cresciuti del 7.3% all'anno negli ultimi 5 anni.

Accelerare la crescita: ABT ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: ABT ha avuto una crescita negativa degli utili ( -61.4% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Medical Equipment ( 13.6% ).

Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 10.5% ) di ABT è considerato basso.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/21 04:16
Prezzo dell'azione a fine giornata2026/08/21 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Abbott Laboratories è coperta da 51 analisti. 26 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
David RescottBaird
Adam FeinsteinBarclays